8-K: Apogee Therapeutics Acquired by AbbVie for $10.9 Billion

Apogee Therapeutics, Inc. announced the completion of its merger with AbbVie Inc., with shareholders receiving $135.11 per share in cash.

Summary

• Apogee Therapeutics, Inc. has been acquired by AbbVie Inc. through a merger, with the transaction closing on September 3, 2026.
• Shareholders of Apogee Therapeutics will receive $135.11 in cash for each share of common stock.
• Options and restricted stock units were converted into cash payments based on the merger consideration.
• The total equity value of the transaction is approximately $10.9 billion, funded by AbbVie through cash and debt.
• Apogee Therapeutics' common stock will be delisted from the Nasdaq Global Market, with trading suspended on September 4, 2026.
• Following the merger, Apogee Therapeutics will operate as an indirect wholly owned subsidiary of AbbVie.
• The company's 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan have been terminated.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, marking the successful completion of a significant acquisition at a premium valuation.

Positives

• Successful completion of the acquisition by AbbVie at a significant valuation of approximately $10.9 billion.
• Shareholders will receive a substantial cash payout of $135.11 per share.
• All outstanding stock options and restricted stock units were converted into cash, providing immediate value to holders.
• The transaction was funded by AbbVie, indicating strong financial backing.
• The company's reporting obligations will be terminated following the delisting, simplifying future compliance.

Negatives

• Apogee Therapeutics will cease to be an independent publicly traded entity.
• Shareholders will no longer have the opportunity to participate in the future growth of Apogee Therapeutics as a standalone company.
• Certain stock options with an exercise price greater than or equal to the merger consideration were cancelled without any payment.

Risks

• Potential for integration challenges as Apogee Therapeutics becomes a subsidiary of AbbVie.
• The filing mentions potential excise taxes on parachute payments for executives, with a cap of $12,500,000 for aggregate payments.
• The company's common stock will be suspended from trading on Nasdaq on September 4, 2026.

Future Outlook

The company will operate as an indirect wholly owned subsidiary of AbbVie. Its common stock will be delisted from Nasdaq, and its reporting obligations under the Exchange Act will be terminated.

Management Comments

• The company's directors voluntarily resigned from the board in connection with the Merger.
• Executive officers no longer serve in their respective positions as of the Effective Time.
• Agreements were entered into with named executive officers to ensure they are in the same after-tax position regarding excise taxes on parachute payments, with an aggregate cap of $12,500,000.

Industry Context

StockSavvy.ai notes that this acquisition by a major pharmaceutical company like AbbVie is consistent with ongoing consolidation trends in the biotechnology and pharmaceutical sectors, where larger companies acquire innovative smaller firms to bolster their pipelines.

Management Changes

Corporate Governance

Legal Proceedings

• No new legal proceedings are detailed in this filing, but the merger agreement itself is a significant legal document.
• The filing references potential excise taxes under Section 4999 of the Internal Revenue Code related to parachute payments.

Related Party Transactions

• The merger agreement involved AbbVie Inc. (Guarantor) and its subsidiaries, which are related parties in the context of the transaction.
• Agreements regarding parachute payments were entered into with named executive officers, which could be considered related party transactions.

Stakeholder Impact

• Shareholders: Receive $135.11 per share in cash, realizing immediate value from their investment.
• Option and RSU Holders: Receive cash payments for vested and unvested options and RSUs.
• Employees: Potential changes in employment terms, benefits, and roles under AbbVie's ownership; termination of existing stock plans.
• Creditors: The acquisition is funded by AbbVie, and the company's obligations are expected to be met.
• Management: Resignations of existing directors and executive officers.

Next Steps

• Trading of Apogee Therapeutics common stock suspended on Nasdaq on September 4, 2026.
• Company to file Form 15 to terminate registration and reporting obligations under the Exchange Act.

Key Dates

Recommendation

The acquisition has been completed at a fixed cash price, meaning the stock is no longer an investment vehicle for future growth. Existing shareholders have received their payout. For potential investors, the opportunity to buy into Apogee Therapeutics as an independent entity has passed. Therefore, a 'hold' recommendation is appropriate for existing shareholders who have received or are awaiting their cash, and 'na' for new investors as the stock is being delisted.

Keywords

Merger, Acquisition, AbbVie, Apogee Therapeutics, Shareholder Payout, Delisting, Cash Consideration, Executive Compensation